We are happy to announce the publication of “Characterisation of the antinociceptive effect of baricitinib in the collagen antibody-induced arthritis mouse model”.
In the paper, published in Annals of the Rheumatic Diseases, first-authors Nils Simon and Resti Rudjito of Karolinska Institutet present their findings around the pain-relieving effect of the JAK inhibitor baricitinib in the context of arthritis. Cellectricon, represented by Lydia Moll, contributed to the study by assessing baricitinib’s influence on neuronal excitability and cell morphology in vitro, using dorsal root ganglion (DRG) cells.
The study, conducted in the Molecular Pain research group of Camilla Svensson, suggests that baricitinib has antinociceptive effects by targeting not only immune cells but also neurons and glia cells via inhibition of two signalling pathways linked to chronic pain.
Full text is available on:
https://ard.eular.org/article/S0003-4967(25)00050-0/abstract